Heller S, Lingvay I, Marso SP, et al. - Researchers applied a hypoglycaemia risk score based on DEVOTE trial data to evaluate whether a high risk of severe hypoglycaemia was correlated with an elevated risk of cardiovascular events, and whether decreased rates of severe hypoglycaemia in patients distinguished as having the highest risk impacted the risk of cardiovascular outcomes. According to patients’ individual hypoglycaemia risk scores, the DEVOTE population was classified into quartiles. For each quartile, they ascertained the observed incidence and rate of severe hypoglycaemia, major adverse cardiovascular event (MACE) and all‐cause mortality to analyze whether those with the highest risk of hypoglycaemia were also at the greatest risk of MACE and all‐cause mortality. The risk score indicated that there were associations between a high risk of severe hypoglycaemia and a high incidence of MACE and all‐cause mortality and that, in this high‐risk group, those treated with degludec had a lower incidence of MACE. These findings helps the hypothesis that hypoglycaemia is a risk factor for cardiovascular events.